Summit Therapeutics (NASDAQ: SMMT) will present at the Barclays 26th Global Healthcare Conference in Miami Beach, FL from March 12-14, 2024. CEO Dr. Maky Zanganeh and Chairman Robert W. Duggan will discuss the innovative investigational bispecific antibody, ivonescimab, on March 12, 2024, at 2:35pm ET. The presentation will be live-streamed on www.smmttx.com, with an archived version available afterward.
Ivonescimab, also known as SMT112 (in Summit’s license territories) and AK112 (in China and Australia), is a potential first-in-class bispecific antibody targeting PD-1 and VEGF. It demonstrates unique cooperative binding to both targets, potentially enhancing efficacy while minimizing side effects. Summit is conducting Phase III clinical trials for ivonescimab in non-small cell lung cancer (NSCLC) after successful enrollment in 2023.
Summit Therapeutics, listed on Nasdaq (symbol: SMMT), aims to develop patient-friendly therapies to address unmet medical needs. For more information, visit https://www.smmttx.com and follow @summitplc on X (formerly Twitter).
Forward-looking statements: This press release may contain statements about the Company’s future expectations, plans, and prospects. Actual results may differ due to various factors, including clinical trial outcomes, regulatory approvals, and global public health crises. The Company disclaims any obligation to update forward-looking statements.
